David A. Siegel Benitec Biopharma Inc. Transaction History

Two Sigma Advisers, LP

  • $41.3 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023
BUY
$0.13 - $5.95 $3,016 - $138,040
23,200 New
23,200 $3,000
Q2 2021

Aug 16, 2021
SELL
$3.94 - $5.81 $46,492 - $68,558
-11,800 Closed
0 $0
Q1 2021

May 17, 2021
SELL
$2.59 - $9.26 $141,002 - $504,123
-54,441 Reduced 82.19%
11,800 $61,000
Q4 2020

Feb 16, 2021
BUY
$2.61 - $4.79 $172,889 - $317,294
66,241 New
66,241 $199,000

Others Institutions Holding BNTC

# of Institutions
2
Shares Held
797K
Call Options Held
0
Put Options Held
0
View Full List

About Benitec Biopharma Inc.

BNTC Quotes by TradingView
  • Ticker BNTC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,809,500
  • Market Cap $299M
  • Description
  • Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal...
More about BNTC
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email